SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
GUILFORD PHARMACEUTICALS INC.
_______________________________________
(Name of Issuer)
Common Stock
_______________________________________
(Title of Class of Securities)
401829106
_______________________________________
(CUSIP Number)
Check the following box if a fee is being paid with this
statement [ ] . (A fee is not required only if the filing
person: (1) has a previous statement on file reporting beneficial
ownership of more than five percent of the class of securities
described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of
such class.) (See Rule 13d-7.)
*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided
in a prior cover page.
The information required in the remainder of this cover page
shall not be deemed to be "filed" for the purpose of Section 18
of the Securities Exchange Act of 1934 ("Act") or otherwise
subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the
Notes).
CUSIP NO. 401829 10 6 13G Page 2 of 4 Pages
1 Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
SCIOS INC. (formerly Scios Nova Inc.)
95-3701481
2 Check the Appropriate Box if a Member of a Group*
NOT APPLICABLE (a) ____
(b) ____
3 SEC Use Only
______________________________
4 Citizenship or Place of Organization
DELAWARE
Number of 5 Sole Voting Power
Shares 1,450,000
Beneficially 6 Shared Voting Power
Owned By Each -0-
Reporting 7 Sole Dispositive Power
Person 1,450,000
With 8 Shared Dispositive Power
-0-
9 Aggregate Amount Beneficially Owned by Each Reporting Person
1,450,000
10 Check Box if the Aggregate Amount in Row (9) Excludes Certain
Shares*
NOT APPLICABLE
11 Percent of Class Represented by Amount in Row 9
10.4%
12 Type of Reporting Person*
CO
*SEE INSTRUCTION BEFORE FILLING OUT
CUSIP NO. 401829106 13G Page 3 of 4 Pages
Item 1(a). Name of Issuer
Guilford Pharmaceuticals Inc.
Item 1(b). Address of Issuer's Principal Executive Offices
6611 Tributary Street
Baltimore, MD 21224
Item 2(a). Name of Person Filing
Scios Inc. (formerly Scios Nova Inc.)
Item 2(b). Address of Principal Business Office
2450 Bayshore Parkway
Mountain View, CA 94043
Item 2(c). Citizenship
Delaware
Item 2(d). Title of Class of Securities
Common Stock
Item 2(e). CUSIP No.
401829 10 6
Item 3. If This Statement Is Filed Pursuant to Rules 13d-1(b) or 13d-2(b)
Not applicable
Item 4. Ownership
(a) Amount Beneficially Owned:
1,450,000
(b) Percent of Class:
10.4%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 1,450,000
(ii) shared power to vote or to direct the vote: None
(iii) sole power to dispose or to direct the disposition of: 1,450,000
(iv) shared power to dispose or to direct the disposition of: None
Item 5. Ownership of Five Percent or Less of a Class
Not applicable
Item 6. Ownership of More Than Five Percent on Behalf of Another Person
Not applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on by the Parent Holding Company
Not applicable
CUSIP NO. 401829106 13G Page 4 of 4 Pages
Item 8. Identification and Classification of Members of the Group
Not applicable
Item 9. Notice of Dissolution of Group
Not applicable
Item 10. Certification
Not applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
Date: February 12, 1997
SCIOS INC.
/s/ John H. Newman
By:_____________________________
John H. Newman
Vice President of Legal Affairs,
General Counsel and Secretary
